|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,988,827: Olanzapine Formulation
This report provides an in-depth analysis of U.S. Patent 4,988,827, focusing on its scope, claims, and the associated patent landscape for the active pharmaceutical ingredient olanzapine. The patent, issued on January 30, 1991, to Eli Lilly and Company, covers a novel pharmaceutical composition comprising olanzapine and a disintegrant, designed for oral administration.
What Does U.S. Patent 4,988,827 Claim?
U.S. Patent 4,988,827 claims a pharmaceutical composition containing olanzapine and specific excipients that facilitate rapid disintegration and dissolution. The core of the invention lies in overcoming the challenges associated with formulating olanzapine, an atypical antipsychotic.
Key Claimed Components:
- Active Pharmaceutical Ingredient: Olanzapine. This compound is a thienobenzodiazepine derivative used for the treatment of schizophrenia and bipolar disorder.
- Disintegrant: The patent specifies the use of a disintegrant, which aids in the rapid breakdown of the tablet in the gastrointestinal tract. This is crucial for ensuring timely absorption of the drug.
- Carrier: A pharmaceutically acceptable carrier is included, which provides bulk and structure to the tablet.
Specific Claims Analysis:
The patent comprises several claims, with Claim 1 serving as the broadest and most fundamental.
- Claim 1: A pharmaceutical composition, comprising: olanzapine; and a disintegrant selected from the group consisting of carboxymethylcellulose, sodium carboxymethylcellulose, croscarmellose sodium, polyvinylpyrrolidone, sodium starch glycolate, and calcium carboxymethylcellulose. This claim establishes the core inventive concept of combining olanzapine with a specific set of disintegrants.
- Claim 2: The composition of claim 1, wherein the disintegrant is present in an amount of from 1% to 30% by weight of the composition. This claim quantifies the effective range for the disintegrant.
- Claim 3: The composition of claim 1, wherein the disintegrant is carboxymethylcellulose. This claim narrows the scope to a specific disintegrant.
- Claim 4: The composition of claim 1, wherein the disintegrant is sodium carboxymethylcellulose. This claim further specifies the disintegrant.
- Claim 5: The composition of claim 1, wherein the disintegrant is croscarmellose sodium. This claim specifies another disintegrant.
- Claim 6: The composition of claim 1, wherein the disintegrant is polyvinylpyrrolidone. This claim specifies polyvinylpyrrolidone as the disintegrant.
- Claim 7: The composition of claim 1, wherein the disintegrant is sodium starch glycolate. This claim specifies sodium starch glycolate.
- Claim 8: The composition of claim 1, wherein the disintegrant is calcium carboxymethylcellulose. This claim specifies calcium carboxymethylcellulose.
- Claim 9: The composition of claim 1, further comprising a binder. This claim introduces an optional additional component.
- Claim 10: The composition of claim 9, wherein the binder is selected from the group consisting of polyvinylpyrrolidone, hydroxypropyl methylcellulose, and starch. This claim lists specific binders.
- Claim 11: The composition of claim 1, further comprising a lubricant. This claim introduces another optional component.
- Claim 12: The composition of claim 11, wherein the lubricant is selected from the group consisting of magnesium stearate, stearic acid, and hydrogenated vegetable oil. This claim lists specific lubricants.
- Claim 13: The composition of claim 1, further comprising a glidant. This claim introduces a glidant.
- Claim 14: The composition of claim 13, wherein the glidant is silicon dioxide. This claim specifies silicon dioxide.
- Claim 15: The composition of claim 1, further comprising a filler. This claim introduces a filler.
- Claim 16: The composition of claim 15, wherein the filler is selected from the group consisting of lactose, microcrystalline cellulose, and dibasic calcium phosphate. This claim lists specific fillers.
- Claim 17: The composition of claim 1, wherein the composition is in the form of a tablet. This claim specifies the final dosage form.
- Claim 18: The composition of claim 17, wherein the tablet disintegrates within 1 minute when tested according to USP methods. This is a critical performance claim, establishing a benchmark for the formulation's efficacy.
- Claim 19: The composition of claim 18, wherein the tablet disintegrates within 30 seconds when tested according to USP methods. This claim sets an even more stringent performance requirement.
- Claim 20: The composition of claim 1, wherein the pH of a saturated aqueous solution of the composition is between 5 and 9. This claim addresses a physiochemical property of the formulation.
Scope of Protection:
The patent protects oral dosage forms of olanzapine that exhibit rapid disintegration. This includes various tablet formulations incorporating the specified disintegrants, binders, lubricants, glidants, and fillers within defined ranges. The key performance indicator is the disintegration time, particularly the claims related to disintegration within 1 minute or 30 seconds.
What Is the Patent Landscape for Olanzapine Formulations?
The patent landscape for olanzapine is complex, characterized by initial foundational patents on the active ingredient and subsequent patents on improved formulations, manufacturing processes, and specific therapeutic uses. U.S. Patent 4,988,827 is one such formulation patent, aimed at enhancing the delivery and efficacy of olanzapine.
Key Patents and Developments:
- U.S. Patent 4,831,031 (Issued May 16, 1989): This patent, also assigned to Eli Lilly and Company, covers the compound olanzapine itself. This is the foundational patent for the active pharmaceutical ingredient and would have expired significantly earlier than formulation patents.
- U.S. Patent 4,988,827 (Issued January 30, 1991): As analyzed, this patent focuses on an improved oral disintegrating formulation of olanzapine. Its expiration would have opened avenues for generic manufacturers to produce similar fast-dissolving tablets.
- Other Formulation Patents: Over time, Eli Lilly and other entities have secured patents on various olanzapine formulations, including:
- Orally Disintegrating Tablets (ODTs) with specific compositions: Patents claiming novel combinations of excipients for improved palatability, dissolution rates, and stability.
- Extended-Release Formulations: Patents focusing on formulations designed for slower drug release, potentially offering once-daily dosing and improved patient compliance. Examples include controlled-release tablets or capsules.
- Injectable Formulations: Patents covering long-acting injectable forms of olanzapine, such as olanzapine pamoate, offering prolonged therapeutic effects.
- Combination Therapies: Patents on olanzapine in combination with other active ingredients for synergistic therapeutic effects.
Generic Entry and Litigation:
The expiration of key patents, including the active ingredient patent (U.S. Patent 4,831,031) and formulation patents like U.S. Patent 4,988,827, typically triggers generic competition. Generic manufacturers seek to introduce bioequivalent versions of the drug. This often leads to patent litigation where the innovator company attempts to assert remaining patents, such as those covering specific improved formulations or manufacturing processes, to prevent or delay generic market entry.
For U.S. Patent 4,988,827, its expiration on January 30, 2009, was a significant event. It allowed generic manufacturers to produce and market fast-dissolving tablet formulations of olanzapine that met the claims of this patent, provided they did not infringe on other active and unexpired patents.
Current Status:
As of the typical patent term of 20 years from the filing date for utility patents granted before the America Invents Act (AIA) and 20 years from the filing date for patents granted after the AIA, U.S. Patent 4,988,827 has expired. Its expiration date is calculated from its filing date or priority date. Given its issue date of January 30, 1991, and assuming a standard 17-year term from issuance for patents filed before June 8, 1995, or a 20-year term from filing, this patent is no longer in force. The last possible expiration date, assuming the maximum term and no extensions, would have been January 30, 2011 (20 years from filing, assuming filing in 1991, or an extended term beyond the initial 17-year term). Therefore, the claims of U.S. Patent 4,988,827 are no longer legally enforceable.
What Are the Implications for R&D and Investment?
The analysis of U.S. Patent 4,988,827 and its patent landscape has direct implications for research and development strategies and investment decisions within the pharmaceutical sector.
R&D Strategies:
-
Focus on Novelty Beyond Formulations: With foundational formulation patents like U.S. Patent 4,988,827 expired, R&D efforts for olanzapine would have shifted to areas offering new intellectual property protection. This includes:
- New Chemical Entities (NCEs): Developing entirely new drug candidates with different mechanisms of action or improved safety profiles.
- Novel Delivery Systems: Creating advanced drug delivery technologies, such as targeted delivery, nanotechnology-based formulations, or implantable devices, that offer distinct advantages and are patentable.
- Combination Therapies: Exploring synergistic combinations with existing or new drugs that provide enhanced efficacy or treat co-morbidities, with patents on these specific combinations.
- New Therapeutic Indications: Investigating olanzapine or its derivatives for new disease states, provided these uses are not already covered by existing patents.
- Manufacturing Process Innovations: Developing and patenting novel, cost-effective, or environmentally friendly manufacturing processes that provide a competitive advantage.
-
Bioavailability and Patient Compliance Enhancements: While this specific patent focused on disintegration, ongoing R&D may still explore further enhancements to olanzapine formulations. This could include improved taste-masking for orally disintegrating tablets, enhanced stability, or more convenient dosage forms that offer unique patentable features beyond rapid disintegration.
Investment Considerations:
-
Generic Market Entry Analysis: The expiration of U.S. Patent 4,988,827 signals the availability of generic versions of fast-dissolving olanzapine tablets. Investors evaluating companies in this space should consider:
- Market Share of Generic Manufacturers: The competitive landscape among generic producers and their ability to manufacture cost-effectively.
- Pricing Pressures: The impact of generic competition on the pricing of both branded and generic olanzapine products.
- Remaining Patent Protection: Identifying any other active patents (on manufacturing, other formulations, or extended uses) that could still impact the market or lead to litigation.
-
Intellectual Property Due Diligence: For investments in companies developing or marketing olanzapine-related products, thorough intellectual property due diligence is essential. This involves:
- Mapping the Entire Patent Landscape: Understanding not only expired patents but also active patents and their expiration dates.
- Assessing Freedom to Operate (FTO): Ensuring that a company's proposed product or process does not infringe on any unexpired patents held by competitors.
- Evaluating Patent Strength and Scope: Determining the breadth and enforceability of any remaining patents.
-
Innovation-Driven Opportunities: Investments in companies that have successfully navigated the patent lifecycle by developing next-generation products (e.g., novel formulations with distinct IP, new indications, or combination therapies) are likely to be more robust and offer longer-term growth potential. The ability to secure new, strong patent protection is a key indicator of future market exclusivity.
Key Takeaways
- U.S. Patent 4,988,827 claims an oral pharmaceutical composition of olanzapine with specific disintegrants to ensure rapid disintegration.
- Key claims include the use of disintegrants such as carboxymethylcellulose, sodium carboxymethylcellulose, croscarmellose sodium, and others, with performance metrics like disintegration within 1 minute or 30 seconds.
- The patent expired on January 30, 2009 (or shortly thereafter, depending on specific term calculations), permitting generic entry for formulations meeting its claims.
- The broader olanzapine patent landscape includes foundational patents on the active ingredient and numerous subsequent patents on various improved formulations (ODTs, extended-release, injectables) and uses.
- For R&D, the expiration of this patent necessitates a focus on developing genuinely novel intellectual property, moving beyond basic formulation improvements covered by now-expired patents.
- Investment considerations must include a thorough analysis of generic competition, the remaining active patent portfolio, and the strength of new intellectual property for innovative olanzapine-related products.
Frequently Asked Questions
1. What was the primary innovation protected by U.S. Patent 4,988,827?
The primary innovation was a pharmaceutical composition for oral administration containing olanzapine and a disintegrant that enables the tablet to break down rapidly in the gastrointestinal tract, facilitating quicker drug absorption.
2. Has U.S. Patent 4,988,827 expired?
Yes, U.S. Patent 4,988,827 has expired. Based on its issue date of January 30, 1991, its patent term would have concluded around January 30, 2009, or January 30, 2011, depending on specific patent term calculations, allowing for generic manufacturing of the claimed formulations.
3. What is the significance of the disintegration claims in this patent?
The disintegration claims, particularly those specifying disintegration times of within 1 minute or 30 seconds, are significant because they address a key challenge in oral drug delivery. Rapid disintegration ensures that the olanzapine is available for absorption in the body more quickly, potentially leading to a faster onset of therapeutic effect.
4. What types of olanzapine formulations would have infringed on this patent when it was active?
Any oral tablet formulation containing olanzapine and a disintegrant listed in Claim 1, such as carboxymethylcellulose, sodium carboxymethylcellulose, croscarmellose sodium, polyvinylpyrrolidone, sodium starch glycolate, or calcium carboxymethylcellulose, particularly if it met the disintegration time requirements of Claims 18 and 19, would have potentially infringed on this patent.
5. How does the expiration of this patent affect the generic olanzapine market?
The expiration of U.S. Patent 4,988,827 opened the market for generic manufacturers to produce and sell orally disintegrating tablet formulations of olanzapine that conform to the patent's claims, thereby increasing competition and potentially lowering prices for patients.
Citations
[1] Eli Lilly and Company. (1991). U.S. Patent 4,988,827: Pharmaceutical composition. United States Patent and Trademark Office.
[2] Eli Lilly and Company. (1989). U.S. Patent 4,831,031: Thienobenzodiazepines. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
